{"entity":{"id":"cun-navarra","kind":"institution","name":"Cancer Center Clínica Universidad de Navarra / CIMA","aka":["CCUN","Clínica Universidad de Navarra","CIMA Universidad de Navarra"],"tldr":"The University of Navarra's cancer centre in Pamplona and Madrid, known for myeloma, immunotherapy research and one of Spain's first proton therapy units.","summary":"The Cancer Center Clínica Universidad de Navarra combines the university hospital's Pamplona and Madrid campuses with the CIMA research centre. Jesús San Miguel and Bruno Paiva have led international myeloma trials and developed next-generation flow cytometry for minimal residual disease, Ignacio Melero's laboratory is a reference in cancer immunotherapy and intratumoural immunostimulation, and Felipe Prósper's group works on cell therapy and gene therapy. The Madrid campus opened a proton therapy unit in 2020, among the first in Spain. The centre is OECI-accredited and offers early-phase trials, CAR-T and comprehensive genomic profiling to private and insured patients.","asOf":"2026-09-09","links":[{"label":"Cancer Center","url":"https://www.cun.es/en"},{"label":"CIMA","url":"https://cima.cun.es/en"}],"tags":[],"related":[],"cancers":["multiple-myeloma","hcc","melanoma","nsclc"],"sections":["immunotherapy","radiation"],"technologies":["proton-therapy","mrd-testing","checkpoint-inhibitor","til-therapy","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":["mrd","abscopal-effect"],"trials":[],"people":["antonio-gonzalez-martin","bruno-sangro","jesus-san-miguel","ignacio-melero"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Pamplona","country":"ES","lat":42.808,"lng":-1.664,"institutionType":"cancer-center","website":"https://www.cun.es/en","university":"Universidad de Navarra","programs":["Multiple myeloma and MRD","Cancer immunotherapy (Melero)","Proton therapy (Madrid)","Cell and gene therapy","CIMA research"]},"route":"/institutions/cun-navarra/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/"},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"institution":[{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/"}],"term":[{"id":"abscopal-effect","kind":"term","name":"Abscopal effect","route":"/terms/abscopal-effect/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}],"person":[{"id":"antonio-gonzalez-martin","kind":"person","name":"Antonio González-Martín","route":"/people/antonio-gonzalez-martin/"},{"id":"bruno-sangro","kind":"person","name":"Bruno Sangro","route":"/people/bruno-sangro/"},{"id":"ignacio-melero","kind":"person","name":"Ignacio Melero","route":"/people/ignacio-melero/"},{"id":"jesus-san-miguel","kind":"person","name":"Jesús San Miguel","route":"/people/jesus-san-miguel/"}]}}